Replies to post #130984 on Biotech Values

[mcbio]

This is primarily the reason why I am in ARIA - like you, I think the T315I population alone would justify ARIA's current market cap.

I thought this was a relatively small patient population. How large is this patient population and what are your projections for ponatinib in this patient population? It would have to be pretty lofty projections for this one population to justify the current ~$1.5B market cap.